Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Cutaneous complications of conventional chemotherapy agents

Aimee S Payne, MD, PhD
Diane MF Savarese, MD
Section Editor
Reed E Drews, MD
Deputy Editor
Rosamaria Corona, MD, DSc


Systemic and local treatments for cancer can cause a number of changes in the skin, mucous membranes, hair, and nails [1-5]. When dermatologic lesions arise in patients being treated for cancer, they may represent a side effect of therapy, but other etiologies need to be considered. These include a cutaneous reaction to other drugs, exacerbation of a previously existing condition, infection, metastatic tumor involvement, a paraneoplastic phenomenon, graft-versus-host disease, or a nutritional disorder.

Accurate diagnosis and management of chemotherapy-related side effects require the clinician to be knowledgeable of the most commonly reported cutaneous reaction patterns for the drugs the patient is receiving. The clinician must also be familiar with the cutaneous manifestations of certain cancers, as well as the dermatologic effects of other forms of cancer treatments. In some cases, diagnostic uncertainty can only be clarified with a rechallenge, and the clinician must determine whether rechallenge is safe and medically justifiable.

The cutaneous complications of conventional cytotoxic cancer therapy agents are presented here. Related topics discussed elsewhere include:

Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy (see "Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy")

Cutaneous manifestations of malignancy (see "Cutaneous manifestations of internal malignancy")


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 14, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.
  2. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995; 33:393.
  3. Remlinger KA. Cutaneous reactions to chemotherapy drugs: the art of consultation. Arch Dermatol 2003; 139:77.
  4. Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33:86.
  5. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 2014; 71:203.e1.
  6. Weiss RB, Baker JR Jr. Hypersensitivity reactions from antineoplastic agents. Cancer Metastasis Rev 1987; 6:413.
  7. Spiegel RJ. The acute toxicities of chemotherapy. Cancer Treat Rev 1981; 8:197.
  8. Foulc P, Evrard V, Dalac S, et al. Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. Br J Dermatol 2002; 147:926.
  9. Estève E, Bagot M, Joly P, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol 1999; 135:1349.
  10. Veelken H, Sklar JL, Wood GS. Detection of low-level tumor cells in allergic contact dermatitis induced by mechlorethamine in patients with mycosis fungoides. J Invest Dermatol 1996; 106:685.
  11. Singal R, Tunnessen WW Jr, Wiley JM, Hood AF. Discrete pigmentation after chemotherapy. Pediatr Dermatol 1991; 8:231.
  12. Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin 2007; 25:215.
  13. Jain V, Bhandary S, Prasad GN, Shenoi SD. Serpentine supravenous streaks induced by 5-fluorouracil. J Am Acad Dermatol 2005; 53:529.
  14. Piraccini BM, Tosti A. Drug-induced nail disorders: incidence, management and prognosis. Drug Saf 1999; 21:187.
  15. Baran R, Laugier P. Melanonychia induced by topical 5-fluorouracil. Br J Dermatol 1985; 112:621.
  16. Pujol RM, Rocamora V, Lopez-Pousa A, et al. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol 1998; 39:839.
  17. Korbitz BC, Reiquam CW. Busulfan in chronic granulocytic leukemia, a spectrum of clinical considerations. Clin Med 1969; 76:16.
  18. Bandini G, Belardinelli A, Rosti G, et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant 1994; 13:577.
  19. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136:1475.
  20. Issaivanan M, Mitu PS, Manisha C, Praveen K. Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review. Pediatr Dermatol 2004; 21:124.
  21. Aste N, Fumo G, Contu F, et al. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol 2002; 47:146.
  22. Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer 1996; 77:1578.
  23. Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 1983; 9:645.
  24. Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 1992; 31:458.
  25. Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008; 58:575.
  26. Schulte-Huermann P, Zumdick M, Ruzicka T. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Dermatology 1995; 191:65.
  27. Baselga E, Drolet BA, Casper J, Esterly NB. Chemotherapy-associated supravenous hyperpigmentation. Dermatology 1996; 192:384.
  28. Todkill D, Taibjee S, Borg A, Gee BC. Flagellate erythema due to bleomycin. Br J Haematol 2008; 142:857.
  29. Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol 1994; 131:700.
  30. Wheeland RG, Burgdorf WH, Humphrey GB. The flag sign of chemotherapy. Cancer 1983; 51:1356.
  31. Holzberg M. Nail signs of systemic disease. In: Atlas of hair and nails, Hordinsky MK, Sawaya ME, Scher RK (Eds), Churchill Livingstone, Philadelphia 2002. p.59.
  32. Alimonti A, Nardoni C, Papaldo P, et al. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res 2005; 25:3531.
  33. Wasner G, Hilpert F, Schattschneider J, et al. Docetaxel-induced nail changes--a neurogenic mechanism: a case report. J Neurooncol 2002; 58:167.
  34. Scotté F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008; 112:1625.
  35. Scotté F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23:4424.
  36. Usuki A, Funasaka Y, Oka M, Ichihashi M. Tegafur-induced photosensitivity--evaluation of provocation by UVB irradiation. Int J Dermatol 1997; 36:604.
  37. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212.
  38. DeSpain JD. Dermatologic toxicity of chemotherapy. Semin Oncol 1992; 19:501.
  39. Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in systemic disease, Smoller BR, Horn TD (Eds), Oxford University Press, New York 2001. p.298.
  40. Fujimoto M, Kikuchi K, Imakado S, Furue M. Photosensitive dermatitis induced by flutamide. Br J Dermatol 1996; 135:496.
  41. Leroy D, Dompmartin A, Szczurko C. Flutamide photosensitivity. Photodermatol Photoimmunol Photomed 1996; 12:216.
  42. Korossy KS, Hood AF. Methotrexate reactivation of sunburn reaction. Arch Dermatol 1981; 117:310.
  43. Guzzo C, Kaidby K. Recurrent recall of sunburn by methotrexate. Photodermatol Photoimmunol Photomed 1995; 11:55.
  44. Williams BJ, Roth DJ, Callen JP. Ultraviolet recall associated with etoposide and cyclophosphamide therapy. Clin Exp Dermatol 1993; 18:452.
  45. Andersen KE, Lindskov R. Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy. Photodermatol 1984; 1:129.
  46. Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology 2003; 207:196.
  47. Badger J, Kang S, Uzieblo A, Srinivas S. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol 2005; 23:7224.
  48. Markman M, Kulp B, Peterson G. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Gynecol Oncol 2004; 94:578.
  49. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33:551.
  50. Baran R, Juhlin L. Photoonycholysis. Photodermatol Photoimmunol Photomed 2002; 18:202.
  51. Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31:818.
  52. Weger W, Kränke B, Gerger A, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol 2008; 59:S4.
  53. Passiu G, Cauli A, Atzeni F, et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol 1999; 18:422.
  54. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 2004; 51:S73.
  55. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58:545.
  56. D'ANGIO GJ, FARBER S, MADDOCK CL. Potentiation of x-ray effects by actinomycin D. Radiology 1959; 73:175.
  57. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59:237.
  58. Schwartz BM, Khuntia D, Kennedy AW, Markman M. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol 2003; 91:421.
  59. Camidge R, Price A. Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol 2002; 20:4130; author reply 4130.
  60. Gzell CE, Carroll SL, Suchowerska N, et al. Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin. Cancer Invest 2009; 27:397.
  61. Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol 1994; 12:439.
  62. Parry BR. Radiation recall induced by tamoxifen. Lancet 1992; 340:49.
  63. Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 2002; 6:535.
  64. Cassady JR, Richter MP, Piro AJ, Jaffe N. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36:946.
  65. Yeo W, Leung SF, Johnson PJ. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33:698.
  66. Stelzer KJ, Griffin TW, Koh WJ. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer 1993; 71:1322.
  67. Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18:693.
  68. Ortmann E, Hohenberg G. Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol 2002; 20:3029.
  69. Boström A, Sjölin-Forsberg G, Wilking N, Bergh J. Radiation recall--another call with tamoxifen. Acta Oncol 1999; 38:955.
  70. Phillips TL, Fu KK. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 1976; 37:1186.
  71. Castellano D, Hitt R, Cortés-Funes H, et al. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18:695.
  72. Greco FA, Brereton HD, Kent H, et al. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976; 85:294.
  73. Greco FA, Oldham RK. Adriamycin and radiation reactions. Ann Intern Med 1977; 86:655.
  74. O'Rourke ME. Enhanced cutaneous effects in combined modality therapy. Oncol Nurs Forum 1987; 14:31.
  75. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22:613.
  76. Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71:787.
  77. Hoff PM, Valero V, Ibrahim N, et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82:965.
  78. Eich D, Scharffetter-Kochanek K, Eich HT, et al. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 2002; 25:599.
  79. Ozmen S, Dogru M, Bozkurt C, Kocaoglu AC. Probable cytarabine-induced acral erythema: report of 2 pediatric cases. J Pediatr Hematol Oncol 2013; 35:e11.
  80. Farr KP, Safwat A. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011; 4:229.
  81. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031.
  82. Sapp CM, DeSimone P. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer 2007; 6:382.
  83. Cohen PR. Acral erythema: a clinical review. Cutis 1993; 51:175.
  84. Hood AF, Haynes HA. Dermatologic complications. In: Cancer Medicine, Holland JF, et al (Eds), Williams & Wilkins, Baltimore p.3141.
  85. Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97:61.
  86. Hellier I, Bessis D, Sotto A, et al. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132:590.
  87. Werchniak AE, Chaffee S, Dinulos JG. Methotrexate-induced bullous acral erythema in a child. J Am Acad Dermatol 2005; 52:S93.
  88. Ozkaya-Bayazit E, Diz-Küçükkaya R, Akasya E, et al. Bullous acral erythema and concomitant pigmentation on the face and occluded skin. J Eur Acad Dermatol Venereol 2000; 14:139.
  89. Azurdia RM, Clark RE, Friedmann PS. Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999; 24:64.
  90. Podjasek JO, Camilleri MJ. Bullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*. J Cutan Pathol 2012; 39:382.
  91. Aytaç S, Gümrük F, Cetin M, et al. Acral erythema with bullous formation: a side effect of chemotherapy in a child with acute lymphoblastic leukemia. Turk J Pediatr 2010; 52:211.
  92. Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009; 15:29.
  93. Chu CY, Yang CH, Yang CY, et al. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 2000; 142:808.
  94. Wong M, Choo SP, Tan EH. Travel warning with capecitabine. Ann Oncol 2009; 20:1281.
  95. Chavarri-Guerra Y, Soto-Perez-de-Celis E. Images in clinical medicine. Loss of fingerprints. N Engl J Med 2015; 372:e22.
  96. Al-Ahwal MS. Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist 2012; 17:291.
  97. van Doorn L, Veelenturf S, Binkhorst L, et al. Capecitabine and the Risk of Fingerprint Loss. JAMA Oncol 2016.
  98. Kim RJ, Peterson G, Kulp B, et al. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 2005; 97:374.
  99. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485.
  100. Levine LE, Medenica MM, Lorincz AL, et al. Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985; 121:102.
  101. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1:225.
  102. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24:457.
  103. Tsuboi H, Yonemoto K, Katsuoka K. A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature. J Dermatol 2005; 32:921.
  104. Weiss RB. Hypersensitivity reactions. In: The Chemotherapy Source Book, 3rd ed, Lippincott, Williams, and Wilkins, Philadelphia 2001. p.442.
  105. Jucglà A, Sais G, Navarro M, Peyri J. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131:364.
  106. Wolf SL, Qin R, Menon SP, et al. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 2010; 28:5182.
  107. Hofheinz RD, Gencer D, Schulz H, et al. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol 2015; 33:2444.
  108. Vukelja SJ, Baker WJ, Burris HA 3rd, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85:1432.
  109. Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8:57.
  110. Kang YK, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010; 28:3824.
  111. von Gruenigen V, Frasure H, Fusco N, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 2010; 116:4735.
  112. Corrie PG, Bulusu R, Wilson CB, et al. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer 2012; 107:585.
  113. Fang XH, Wu Q, Han XM, et al.. High dose pyridoxine for the prevention of hand-foot syndrome caused by capecitabine. Oncology 2010; 30:1081.
  114. Chalermchai T, Tantiphlachiva K, Suwanrusme H, et al. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia Pac J Clin Oncol 2010; 6:155.
  115. Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. PLoS One 2013; 8:e72245.
  116. Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 2014; 22:1585.
  117. Molpus KL, Anderson LB, Craig CL, Puleo JG. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 2004; 93:513.
  118. Mangili G, Petrone M, Gentile C, et al. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008; 108:332.
  119. Drake RD, Lin WM, King M, et al. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004; 94:320.
  120. Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007; 18 Suppl 6:vi70.
  121. Harrist TJ, Fine JD, Berman RS, et al. Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol 1982; 118:263.
  122. Bailey DL, Barron D, Lucky AW. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Pediatr Dermatol 1989; 6:33.
  123. Margolis DJ, Gross PR. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Cutis 1991; 48:198.
  124. Thorisdottir K, Tomecki KJ, Bergfeld WF, Andresen SW. Neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1993; 28:775.
  125. Brehler R, Reimann S, Bonsmann G, Metze D. Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Am J Dermatopathol 1997; 19:73.
  126. Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in systemic disease, Smoller BR, Horn TD (Eds), Oxford University Press, New York 2001. p.298.
  127. Bernstein EF, Spielvogel RL, Topolsky DL. Recurrent neutrophilic eccrine hidradenitis. Br J Dermatol 1992; 127:529.
  128. Beutner KR, Packman CH, Markowitch W. Neutrophilic eccrine hidradenitis associated with Hodgkin's disease and chemotherapy. A case report. Arch Dermatol 1986; 122:809.
  129. Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1996; 35:819.
  130. Flynn TC, Harrist TJ, Murphy GF, et al. Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. J Am Acad Dermatol 1984; 11:584.
  131. Böckle BC, Baltaci M, Weyrer W, Sepp NT. Bortezomib-induced lupus erythematosus tumidus. Oncologist 2009; 14:637.
  132. Gerecitano J, Goy A, Wright J, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006; 134:391.
  133. Nardone B, Wu S, Garden BC, et al. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk 2013; 13:424.
  134. Wäsch R, Jakob T, Technau K, et al. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Ann Hematol 2012; 91:287.
  135. Allegra A, Alonci A, Penna G, et al. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. Hematol Oncol 2012; 30:41.
  136. Castaneda CP, Brandenburg NA, Bwire R, et al. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol 2009; 27:156.
  137. Thödtmann R, Sauter T, Weinknecht S, et al. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003; 21:353.
  138. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20:3533.
  139. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.
  140. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556.
  141. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.
  142. Lopes G, Vincek V, Raez LE. Pemetrexed-associated urticarial vasculitis. Lung Cancer 2006; 51:247.
  143. Eguia B, Ruppert AM, Fillon J, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol 2011; 6:2083.
  144. D'Angelo SP, Kris MG, Pietanza MC, et al. A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed. J Thorac Oncol 2011; 6:624.
  145. Grey MR, Flanagan NG, Kelsey PR. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin Lab Haematol 2000; 22:111.
  146. Lee TC, Hook CC, Long HJ. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc 1994; 69:80.
  147. Bencini PL, Sala F, Crosti C, et al. Exfoliative dermatitis following intravesical therapy with mitomycin C. Int J Dermatol 1985; 24:472.
  148. Peters T, Theile-Ochel S, Chemnitz J, et al. Exfoliative dermatitis after long-term methotrexate treatment of severe psoriasis. Acta Derm Venereol 1999; 79:391.
  149. Kunkeler L, Nieboer C, Bruynzeel DP. Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Dermatitis 2000; 42:74.
  150. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490.
  151. Dissemond J, Körber A. Hydroxyurea-induced ulcers on the leg. CMAJ 2009; 180:1132.
  152. Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 1999; 135:818.
  153. Weinlich G, Schuler G, Greil R, et al. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39:372.
  154. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128:29.